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L E T T E R  T O  T H E  E D I T O R
Measurement of factor VIII activity of efraloctocog alfa with 
commercially available one- stage clotting and chromogenic 
assays: Results from the Belgian national External Quality 
Assessment Scheme
Sir,
Modified factor VIII (FVIII) and factor IX products with extended 
half- lives (EHL) are currently being introduced into routine clinical 
practice. The modification applied to these molecules has intro-
duced variations in their activity measurement, and some marked 
differences between the results of different assays have been de-
scribed for some EHL FVIII and EHL FIX.1-4 However, accurate 
measurement of these clotting factors is essential to avoid under- or 
overtreatment of patients and an unnecessary search for inhibitor 
antibodies.1
Efraloctocog alfa (Elocta®, rFVIIIFc) is an EHL FVIII from Biogen/
SOBI composed of a single molecule of B- domain- deleted recombi-
nant FVIII (rFVIII) covalently linked to the Fc domain of human IgG1 
to extend the circulating half- life of rFVIII.5
This study aimed to assess the performance of the activated par-
tial thromboplastin time (aPTT)- based one- stage clotting assays and 
chromogenic methods used in the Belgian and Luxembourg clinical 
laboratories for measuring factor VIII activity (FVIII:C) in samples 
containing rFVIIIFc.
1  | METHODS
1.1  | Sample material and distribution
For this purpose, the Belgian national External Quality Assessment 
Scheme (EQAS) for blood coagulation organized in December 2016 
a survey which included a sample from a patient with severe hae-
mophilia A collected 1 hour after infusion of 4000 U of rFVIIIFc and 
obtained following informed consent. The sample was collected 
into 0.106 mol/L citrate. After centrifugation and separation, the 
plasma was buffered with HEPES and lyophilized prior to distribu-
tion through the post at room temperature. The sample was tested 
negative for hepatitis B surface antigen and antibodies to hepatitis C 
virus and human immunodeficiency viruses 1 and 2.
1. 2  | Sample analysis
Participants were requested to reconstitute the lyophilized plasma 
with 1.0 mL distilled water and to incubate it with gentle mixing for 
at least 15 minutes at room temperature before analysis. They were 
asked to determine FVIII:C according to their usual procedures and 
to record the reagents and analyser used for testing.
1.3  | Statistical analysis
Method- specific medians and robust standard deviations were 
calculated for all methods with ≥6 reported results (interquartile 
range- based method of Tukey). Differences between methods were 
assessed by means of non- parametric statistics (Wilcoxon signed 
rank test with subsequent Bonferroni correction of the P- values). P- 
values < 0.05 were considered to be statistically significant.
2 | RESULTS
All 54 Belgian and Luxembourg clinical laboratories performing 
FVIII:C testing participated in the survey. Of them, 44 used a one- 
stage clotting assay, eight a one- stage clotting and a chromogenic 
assay, one laboratory a one- stage clotting and two chromogenic as-
says and one participant only a chromogenic method.
In total, nine different one- stage aPTT- based clotting assays and 
four different chromogenic methods were used.
The nine aPTT reagents were as follows: SynthasIL® (Werfen, 
Milan, Italy, 23 participants), Actin FS® (Siemens Healthcare 
Diagnostics, Marburg, Germany, 13 participants), STA- 
Cephascreen® (Diagnostica Stago, Asnières, France, six partici-
pants), STA- PTT A® (Diagnostica Stago, three participants), STA- CK 
Prest® (Diagnostica Stago, three participants), APTT- SP® (Werfen, 
one participant) and Actin®, Actin FSL® and Pathromtin SL® (all 
Siemens Healthcare Diagnostics and one participant). The charac-
teristics of the aPTT reagents are summarized in Table 1. Except 
for three laboratories, all participants used aPTT reagent, calibra-
tion plasma, factor- deficient plasma and instrument from the same 
manufacturer.
The four chromogenic assays were as follows: Biophen FVIII:C® 
(Hyphen BioMed, Neuville- sur- Oise, France, four participants), 
Trinichrom Factor VIII:C® (Diagnostica Stago, three participants), 
Coamatic Factor VIII® (Chromogenix, Milan, Italy, three partici-
pants) and Factor VIII Chromogenic Assay® (Siemens Healthcare 
Diagnostics, one participant).
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The results obtained by the one- stage clotting assays and chro-
mogenic methods are summarized in Table 2. The overall median 
FVIII:C was 58.0 IU/dL with a coefficient of variation (CV) of 16.7% 
(range: 43.0- 74.0 IU/dL). The results obtained with the chromogenic 
assays were slightly but significantly higher than those obtained 
with the one- stage clotting assays (median: 61.0 IU/dL, range: 50.1- 
74.0 IU/dL vs median: 57.4 IU/dL, range: 43.0- 74.0 IU/dL, P = 0.038).
Three aPTT reagents were used in sufficient numbers for statis-
tical analysis. The results obtained with Actin FS® were slightly but 
significantly lower (median: 48.0 IU/dL, range: 43.0- 62.4 IU/dL) than 
those obtained with SynthasIL® (median: 58.6 IU/dL, range: 47.1- 
68.0 IU/dL, P = 0.015) or STA- Cephascreen® (median: 63.5 IU/dL, 
range: 56.0- 74.0 IU/dL, P = 0.029).
All one- stage and chromogenic assays were calibrated with a 
plasma calibrator. Irrespective of the method employed, median 
FVIII:C was 57.7 IU/dL with a CV of 17.1% (range: 46.0- 68.0 IU/dL, n: 
28), 54.0 IU/dL with a CV of 14.6% (range: 43.0- 62.4 IU/dL, n: 19) and 
62.4 IU/dL with a CV of 8.9% (range: 51.0- 74.0 IU/dL, n: 14), when 
assay calibration was performed with HemosIL Calibration Plasma 
(Werfen), Standard Human Plasma (Siemens Healthcare Diagnostics) 
and STA- Unicalibrator (Diagnostica Stago), respectively. There was 
only a significant difference between the results obtained with the 
Stago and Siemens calibration plasma (P = 0.0017). Table 3 shows 
the chromogenic FVIII assay results in relation to the calibrator used. 
For the Biophen FVIII:C reagent, results tended to be slightly higher 
when the Biophen Plasma Calibrator (Hyphen BioMed) was used for 
assay calibration.
3 | DISCUSSION
This study was carried out to provide the Belgian and Luxembourg 
clinical laboratories performing FVIII:C testing with detailed 
information on the measurement of postinfusion rFVIIIFc lev-
els as performed with a large number of reagent/instrument 
combinations.
Overall, a good agreement between the results was seen and 
none of the results deviated by more than 30% of the overall me-
dian value, which is the maximum bias that has been considered as 
acceptable.4
In 2014, the authors of a comparative field study on rFVIIIFc 5 
reported around 25% higher recovery with chromogenic methods 
compared to one- stage clotting assays in samples containing >22 IU/dL 
rFVIIIFc but they did not provide data on individual reagents. In our 
study, the results obtained with the chromogenic assays were only 
slightly higher than those obtained with the one- stage clotting as-
says (median of 61.0 vs 57.4 IU/dL). The difference between the two 
methodologies was most pronounced for the one- stage clotting as-
says using Actin FS® (median of 48.0 IU/dL). Thus, our results support 
the conclusions of the authors of the comparative field study, stating 
that both one- stage clotting assays and chromogenic  methods can 
be used for monitoring rFVIIIFc.
Given the fact that all assays used in this study were calibrated 
with a plasma calibrator, our results confirm that a product- specific 
standard is not required for measuring FVIII:C in samples containing 
rFVIIIFc.3
TABLE  1 Summary of characteristics of aPTT reagents
Reagent Activator
Phospholipid 
source
Siemens Actin Ellagic acid Cephalin from 
rabbit brain
Siemens Actin FS Ellagic acid Soya bean 
phosphatides
Siemens Actin FSL Ellagic acid Soya bean and 
rabbit brain 
phosphatides
Siemens Pathromtin SL Silica Vegetable 
phospholipids
Stago STA- CK PREST Kaolin Cephalin from 
rabbit brain
Stago STA- Cephascreen Polyphenols Cephalin from 
rabbit brain
Stago STA- PTT A Silica Cephalin from 
rabbit brain
Werfen SynthasIL Colloidal silica Synthetic 
phospholipids
Werfen APTT- SP Silica Synthetic 
phospholipids
TABLE  2 Summary of FVIII assay results. Method- specific 
medians (IU/dL) and coefficients of variation (CV, %) are shown for 
all methods with ≥6 reported results. Results (IU/dL) are presented 
individually for the other methods
Method Median (CV) Results N
One- stage aPTT- 
based clotting assay
57.4 (16.0) 53
 SynthasIL 58.6 (14.1) 23
 Actin FS 48.0 (15.9) 13
 STA- Cephascreen 63.5 (10.5) 6
 STA- CK PREST 63.8, 64.0, 66.0 3
 STA- PTT A 51.0, 54.0, 60.0 3
 APTT- SP 46.0, 48.8 2
 Actin 59.0 1
 Actin FSL 55.4 1
 Pathromtin SL 62.0 1
Chromogenic method 61.0 (9.7) 11
 Biophen FVIII:C 57.9, 58.0, 72.0, 
74.0
4
 Coamatic factor VIII 58.0, 65.0, 66.0 3
 Trinichrom factor 
VIII:C
58.0, 61.0, 66.0 3
 Factor VIII  
chromogenic assay
50.1 1
Global result 58.0 (16.7) 64
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Strong points of our study include the use of a sample collected 
from a patient after infusion of rFVIIIFc and the inter- laboratory set-
ting and variety of reagent/instrument combinations employed. A 
limitation of our study is the fact that we investigated the perfor-
mance of the assays at only one concentration.
In conclusion, the results of this study show that both one- 
stage clotting assays and chromogenic methods as routinely used 
in Belgian and Luxembourg clinical laboratories provide acceptable 
values of postinfusion rFVIIIFc levels in the normal range, allowing 
an adequate monitoring of patients treated with this product.
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Reagent + calibrator Results N
Hyphen BioMed Biophen FVIII:C + 
Hyphen BioMed Biophen Plasma Calibrator
72.0, 74.0 2
Hyphen BioMed Biophen FVIII:C + 
Siemens Standard Human Plasma
58.0 1
Hyphen BioMed Biophen FVIII:C + 
In- house pooled normal plasma calibrated against 
Werfen HemosIL Calibration Plasma
57.9 1
Chromogenix Coamatic Factor VIII + 
Werfen HemosIL Calibration Plasma
58.0, 65.0, 66.0 3
Stago Trinichrom Factor VIII:C + 
Stago STA- Unicalibrator
61.0, 66.0 2
Stago Trinichrom Factor VIII:C + 
Siemens Standard Human Plasma
58.0 1
Siemens Factor VIII chromogenic assay + 
Siemens Standard Human Plasma
50.1 1
TABLE  3 Chromogenic FVIII assay 
results in relation to the calibrator used
